Skip to content


  • Study protocol
  • Open Access
  • Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Evaluation of the immunogenicity and safety of different doses and formulations of a broad spectrum influenza vaccine (FLU-v) developed by SEEK: study protocol for a single-center, randomized, double-blind and placebo-controlled clinical phase IIb trial

  • Eva van Doorn1Email author,
  • Olga Pleguezuelos2,
  • Heng Liu1,
  • Ana Fernandez2,
  • Robin Bannister2,
  • Gregory Stoloff2,
  • Fredrik Oftung3,
  • Stephen Norley4,
  • Anke Huckriede5,
  • Henderik W. Frijlink6 and
  • Eelko Hak1
BMC Infectious DiseasesBMC series – open, inclusive and trusted201717:241

Received: 30 November 2016

Accepted: 24 March 2017

Published: 4 April 2017

Back to article

Open Peer Review reports

Pre-publication versions of this article are available by contacting

Original Submission
30 Nov 2016 Submitted Original manuscript
7 Dec 2016 Author responded Author comments - Eva van Doorn
Resubmission - Version 2
7 Dec 2016 Submitted Manuscript version 2
28 Feb 2017 Reviewed Reviewer Report - Victor Huber
8 Mar 2017 Reviewed Reviewer Report - Karl Albert Brokstad
21 Mar 2017 Author responded Author comments - Eva van Doorn
Resubmission - Version 3
21 Mar 2017 Submitted Manuscript version 3
24 Mar 2017 Editorially accepted
4 Apr 2017 Article published 10.1186/s12879-017-2341-9

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting

You can find further information about the peer review system here.

Authors’ Affiliations

University of Groningen, Unit of PharmacoTherapy- Epidemiology & -Economics, Antonius Deusinglaan, Groningen, The Netherlands
SEEK, London, UK
Norwegian Institute of Public Health, Department of Infectious Disease Immunology, Oslo, Norway
Robert Koch Institute, Berlin, Germany
University Medical Center Groningen, Medical Microbiology, Groningen, The Netherlands
Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, The Netherlands